Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept Modified Treat-and-Extend in nAMD
NCT05539235Phase 3Unknown
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2018
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of conbercept in exudative age-related macular degeneration, sponsored by First Affiliated Hospital of Chongqing Medical University. Status: unknown.
02
Drugs
conbercept
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT05539235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539235.